Skip to main content

Advertisement

SpringerLink
Log in

Relationship between serum 1,25-dihydroxyvitamin D and mortality in patients with pre-dialysis chronic kidney disease

  • Original Article
  • Published:
Clinical and Experimental Nephrology Aims and scope Submit manuscript

Abstract

Background

It is known that vitamin D has many functions besides involvement in calcium metabolism. It has recently been recognized that vitamin D deficiency is associated with mortality, especially in cardiovascular disease (CVD). Vitamin D deficiency is common in end-stage renal disease, but develops from the early stage of chronic kidney disease (CKD). So we investigated whether the serum level of the activated form of vitamin D (1,25-dihydroxyvitamin D) affected mortality in patients with CKD stages 3 and 4.

Methods

Between January 1, 1995, and June 30, 2006 we measured serum 1,25-dihydroxyvitamin D In 226 patients with CKD stages 3 and 4 and classified the results into two groups depending on whether the level was below (group I) or above (group II) 20 pg/ml. We ended the follow-up period on December 31, 2006. We compared all-cause and cardiovascular mortality between the two groups. We also examined predictors of mortality by using Cox proportional regression analysis.

Results

Two-hundred and twenty-six patients (67 men and 159 women, mean age 67.0) were registered in this study, and groups 1 and 2 comprised 84 and 142 patients, respectively. During the follow-up period 43 patients died. CVD was the major cause of death, followed by infectious disease. The Kaplan–Meier survival curve revealed that all-cause mortality was significantly higher in group I, but a significant difference between CVD mortality in the two groups was not demonstrated. By Cox proportional regression analysis, group I was related to all-cause mortality, but this was not proved to be an independent predictor.

Conclusion

The results suggested that serum level of 1,25-dihydroxyvitamin D was associated with all-cause mortality in patients with CKD stages 3 and 4.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Slatopolsky E, Brown A, Dusso A. Pathogenesis of secondary hyperparathyroidism. Kidney Int. 1999;73:S14–9.

    Article  CAS  Google Scholar 

  2. Andress DL. Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int. 2006;69:33–43.

    Article  CAS  PubMed  Google Scholar 

  3. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Andress DL. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007;71:31–8.

    Article  CAS  PubMed  Google Scholar 

  4. Fraga C, Blanco M, Vigo E, Segura C, Garcia-Caballero T, Perez-Fernandez R. Ontogenesis of the vitamin D receptor in rat heart. Histochem Cell Biol. 2002;117:547–50.

    Article  CAS  PubMed  Google Scholar 

  5. Suda T, Jimi E, Nakamura I, Takahashi N. Role of 1 alpha, 25-dihydroxyvitamin D3 in osteoclast differentiation and function. Methods Enzymol. 1997;282:223–35.

    Article  CAS  PubMed  Google Scholar 

  6. Major GC, Alarie F, Dore J, Phouttama S, Tremblay A. Supplementation with calcium + vitamin D enhances the beneficial effect of weight loss on plasma lipid and lipoprotein concentrations. Am J Clin Nutr. 2007;85:54–9.

    CAS  PubMed  Google Scholar 

  7. Imazeki I, Matsuzaki J, Tsuji K, Nishimura T. Immunomodulating effect of vitamin D3 derivatives on type-1 cellular immunity. Biomed Res. 2006;27:1–9.

    Article  CAS  PubMed  Google Scholar 

  8. Remuzzi A. Vitamin D, insulin resistance, and renal disease. Kidney Int. 2007;71:96–8.

    Article  CAS  PubMed  Google Scholar 

  9. Levin A, Li YC. Vitamin D and its analogues: do they protect against cardiovascular disease in patients with kidney disease? Kidney Int. 2005;68:1973–81.

    Article  CAS  PubMed  Google Scholar 

  10. Luong KVQ, Nguyen LTH. Vitamin D and cardiovascular disease. Curr Med Chem. 2006;13:2443–7.

    Article  CAS  PubMed  Google Scholar 

  11. Levey AS, Bosch JP, Lewis JB, Greene T, Rodgers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med. 1999;130:461–70.

    Article  CAS  PubMed  Google Scholar 

  12. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1–226.

    Google Scholar 

  13. Imai E, Horio M, Nitta K, Yamagata K, Iseki K, Hara S, Ura N, Kiyohara Y, Hirakata H, Watanabe T, Moriyama T, Ando Y, Inaguma D, Narita I, Iso H, Wakai K, Yasuda Y, Tsukamoto Y, Ito S, Makino H, Hishida A, Matsuo S. Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease. Clin Exp Nephrol. 2007;11:41–50.

    Article  PubMed  Google Scholar 

  14. Haussler MR, Whitfield GK, Haussler CA, Hsieh JC, Thompson PD, Selznick SH, Dominquez CE, Jurutka PW. The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res. 1998;13:325–49.

    Article  CAS  PubMed  Google Scholar 

  15. O’Connell TD, Simpson RU. Immunochemical identification of the 1,25-dihydroxyvitamin D3 receptor protein in human heart. Cell Biol Int. 1996;20:621–4.

    Article  PubMed  Google Scholar 

  16. Sandgren ME, Bronnegard M, DeLuca HF. Tissue distribution of the 1,25-dihydroxyvitamin D3 receptor in the male rat. Biochem Biophys Res Commun. 1991;181:611–6.

    Article  CAS  PubMed  Google Scholar 

  17. Cardus A, Parisi E, Gallego C, Aldea M, Fernandez E, Valdivielso JM. 1,25-Dihydroxyvitamin D3 stimulates vascular smooth muscle cell proliferation through a VEGF-mediated pathway. Kidney Int. 2006;69:1377–84.

    Article  CAS  PubMed  Google Scholar 

  18. Chonchol M, Scragg R. 25-Hydroxyvitamin D, insulin resistance, and kidney function in the third national health and nutrition examination survey. Kidney Int. 2006;71:134–9.

    Article  PubMed  Google Scholar 

  19. Zittermann A, Schleithoff SS, Tenderich G, Berthold HK, Korfer R, Stehle P. Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure? J Am Coll Cardiol. 2003;41:105–12.

    Article  CAS  PubMed  Google Scholar 

  20. Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr. 2006;83:754–9.

    CAS  PubMed  Google Scholar 

  21. Bishop JE, Collins ED, Okamura WH, Norman AW. Profile of ligand specificity of the vitamin D binding protein for 1 alpha, 25-dihydroxyvitamin D3 and its analogs. J Bone Miner Res. 1994;9:1277–88.

    Article  CAS  PubMed  Google Scholar 

  22. Guoth M, Murgia A, Smith RM, Prystowsky MB, Cooke NE, Haddad JG. Cell surface vitamin D-binding protein (GC-globulin) is acquired from plasma. Endocrinology. 1990;127:2313–21.

    Article  CAS  PubMed  Google Scholar 

  23. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med. 2003;349:446–56.

    Article  CAS  PubMed  Google Scholar 

  24. Shoji T, Shinohara K, Kimoto E, Emoto M, Tahara H, Koyama H, Inaba M, Fukumoto S, Ishimura E, Miki T, Tabata T, Nishizawa Y. Lower risk for cardiovascular mortality in oral 1α-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant. 2004;19:179–84.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nephrology and Rheumatology, Tosei General Hospital, Nishioiwake-cho 160, Seto, Aichi, 489-8642, Japan

    Daijo Inaguma, Hiroshi Nagaya, Kazuhiro Hara, Miho Tatematsu, Hibiki Shinjo, Sachiyo Suzuki, Tomoko Mishima & Kei Kurata

Authors
  1. Daijo Inaguma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hiroshi Nagaya
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kazuhiro Hara
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Miho Tatematsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hibiki Shinjo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sachiyo Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tomoko Mishima
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kei Kurata
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daijo Inaguma.

About this article

Cite this article

Inaguma, D., Nagaya, H., Hara, K. et al. Relationship between serum 1,25-dihydroxyvitamin D and mortality in patients with pre-dialysis chronic kidney disease. Clin Exp Nephrol 12, 126–131 (2008). https://doi.org/10.1007/s10157-007-0023-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10157-007-0023-4

Keywords

Search

Navigation